for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Immunovia AB (publ)

IMMNOV.ST

Latest Trade

148.40SEK

Change

-3.20(-2.11%)

Volume

2,927

Today's Range

144.00

 - 

151.60

52 Week Range

128.00

 - 

188.80

As of on the Stockholm Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
151.60
Open
144.00
Volume
2,927
3M AVG Volume
0.35
Today's High
151.60
Today's Low
144.00
52 Week High
188.80
52 Week Low
128.00
Shares Out (MIL)
19.53
Market Cap (MIL)
2,960.95
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Immunovia Q2 Loss Before Tax Widens To SEK 29.9 Million

Immunovia and Erlangen University Hospital Enter Into A Collaboration Agreement

Immunovia's CEO Sells 48,000 Immunovia Shares

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Immunovia AB (publ)

Immunovia publ AB is a Sweden-based company engaged in the life science sector. The Company offers its services through its technology platform based on antibody microarray analysis, IMMray, which is dedicated to the diagnosis of cancer, to predicting disease progression and to monitoring the therapeutic responsiveness of cancers. The Company’s technology is designed not only for cancer but also for autoimmune diseases. The Company has its own antibody library, antibody production and purification, as well as its own chip/array production. The Company’s in-house recombinant antibody production and purification platform provides antibodies for microarray fabrication. The Company has on-going projects targeting other cancers, such as prostate cancer, as well as autoimmune diseases, such as systemic lupus erythematosus.

Industry

Biotechnology & Drugs

Contact Info

Medicon Village, Scheelevagen 2

+46.46.2756000

http://immunovia.com

Executive Leadership

Carl Borrebaeck

Chairman of the Board

Mats Grahn

Chief Executive Officer

Hans Liljenborg

Chief Financial Officer

Lotta Blomgren

Operations Director

Henrik Winther

Senior Vice President Business Development

Key Stats

1.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, SEK)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
Price To Earnings (TTM)
--
Price To Sales (TTM)
7,465.84
Price To Book (MRQ)
7.31
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
8.23
LT Debt To Equity (MRQ)
7.22
Return on Investment (TTM)
-21.19
Return on Equity (TTM)
-20.11

Latest News

Latest News

BRIEF-Immunovia Q4 Pretax Loss Widens To SEK 25.7 Mln

* REPORTED ON THURSDAY Q4 NET SALES SEK 91,000 VS SEK 26,000 YR AGO

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up